UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of September 2022
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including Zip Code, and Telephone
Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ¨ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Termination of a Material Definitive Agreement
On September 19, 2022 (the “Notice Date”), ProQR Therapeutics N.V. (the “Company") entered into a pay-off letter (the “Pay-Off Letter”) with Pontifax Medison Finance (Israel) L.P., Pontifax Medison Finance (Cayman) L.P., Kreos Capital VI (UK) Limited, Kreos Capital 2020 Opportunity (UK) Limited, Kreos Capital 2020 Opportunity Limited and Kreos Capital VI (Expert Fund) L.P. (each, a “Lender” and collectively, the “Lenders”) and Pontifax Medison Finance GP, L.P., in its capacity as administrative agent and collateral agent for itself and Lenders (in such capacity, including any successor thereto, the “Agent” and, together with the Lenders, the “Lender Parties”). The Pay-Off Letter acknowledges and confirms that the Company has previously delivered a written notice of prepayment notifying the Lender Parties that it intends to (i) prepay in full the entire principal balance of the loans (the “Loans”) currently outstanding, including all accrued and unpaid interest thereon, under that certain Loan and Security Agreement, dated as of July 14, 2020 (as amended by that certain Joinder and First Amendment to Loan Agreement and Joinder to Registration Rights Agreement, dated as of August 4, 2020, that certain Second Amendment to Loan Agreement, dated as of January 5, 2021, that certain Third Amendment to Loan and Security Agreement, dated as of December 29, 2021, and as further amended, supplemented, modified and/or restated from time to time and in effect immediately prior to the Notice Date, the “Loan and Security Agreement”; capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Loan and Security Agreement) and (ii) pay and satisfy in full all other amounts and obligations outstanding under the Loan and Security Agreement and the other Loan Documents (together with the Loans, collectively, the “Indebtedness”), in each case, in accordance with the terms of the Loan and Security Agreement and the other Loan Documents, as applicable. The Pay-Off Letter provides that (i) the aggregate prepayment amount in connection with the Indebtedness, together with a prepayment charge equal to one percent (1%) of the principal amount being prepaid, will be approximately $42.7 million (the “Pay-Off Amount”) and (ii) upon receipt by the Agent of payment in full of the Pay-Off Amount, all liens, encumbrances and security interests of the Lender Parties will be automatically and irrevocably released and terminated, and all liabilities, obligations and indebtedness owed by the Company to the Lender Parties will be satisfied and discharged in full.
The Company paid in full the Pay-Off Amount to the Lender Parties on September 21, 2022. Following such payment and satisfaction, the Loan and Security Agreement and all other Loan Documents were terminated, canceled and of no further force and effect in accordance with their terms (other than inchoate indemnity obligations or other contingent obligations which, by their terms, survive termination), and no further borrowings may be made thereunder.
The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File No. 333-260775, File No. 333-260780 and File No. 333-248740).
Other Information
Following the payment in full of the Pay-Off Amount, the Company expects that its cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into 2026.
Forward-Looking Statements
This Report of Foreign Private Issuer on Form 6-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding the Company’s business operations, financial position and cash runway. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this Report of Foreign Private Issuer on Form 6-K. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in the Company’s filings made with the Securities and Exchange Commission. These risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission. All forward-looking statements contained in this Report of Foreign Private Issuer on Form 6-K speak only as of the date on which they were made and should not be relied upon as representing its views as of any subsequent date. The Company undertakes no obligation to update such forward-looking statements, even if new information becomes available in the future, except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PROQR THERAPEUTICS N.V. | ||
| Date: September 21, 2022 | By: | /s/ René Beukema |
| René Beukema | ||
| Chief Corporate Development Officer and General Counsel | ||